Back

Use of emgliflozine in cardiotoxicity treatment. EMPACARD-treatment registry. Six-months follow-up

27 August 2022 (11:15 - 11:55)
Organised by:
Congress Presentation Part of: Cardio-oncology 4 Cardio-Oncology ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Doctor Andres Jose Daniele

Institute of Oncology Angel H. Roffo, Buenos Aires (Argentina)

6 More presentations in this session

Presentation thumbnail
Basal characteristics of the prospective spanish immunotherapy registry of cardiovascular toxicity: SIR-CVT
Doctor E. Zatarain-Nicolas (Madrid, ES)
Abstract Slides
Presentation thumbnail
The prognostic significance of troponin level in patients with malignancy (NIHR Health Informatics Collaborative TROP-MALIGNANCY study)
Doctor A. Kaura (London, GB)
Abstract Slides
Presentation thumbnail
COVID-19 and acute heart failure among patients with cancer
Doctor M. Bergami (Bologna, IT)
Abstract Slides
Presentation thumbnail
Effect of 1st line treatment on aortic inflammation as assessed by 18 FDG PET/CT in patients with Hodgkin and non-Hodgkin lymphoma
Doctor D. Terentes-Printzios (Athens, GR)
Abstract Slides
Presentation thumbnail
Prognostic impact of coronary artery calcifications in patients with newly diagnosed prostate cancer
Doctor N. Stoedkilde-Joergensen (Aarhus, DK)
Abstract Slides

Access the full session

Session thumbnail
Cardio-oncology 4

The Event

Event poster

ESC Congress 2022

27 August 2022 11:15 CET

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources